Background/aim: Stimulation of the retina with flickering light increases retinal arterial and venous diameters in animals and humans, indicating a tight coupling between neural activity and blood flow. The aim of the present study was to investigate whether this response is altered in patients with insulin dependent diabetes mellitus.

Methods: 26 patients with diabetes mellitus with no or mild non-proliferative retinopathy and 26 age and sex matched healthy volunteers were included in the study. Retinal vessel diameters were measured continuously with the Zeiss retinal vessel analyser. During these measurements three episodes of square wave flicker stimulation periods (16, 32, and 64 seconds; 8 Hz) were applied through the illumination pathway of the vessel analyser.

Results: In retinal arteries, the response to stimulation with diffuse luminance flicker was significantly diminished in diabetic patients compared to healthy volunteers (ANOVA, p<0.0031). In non-diabetic controls flicker stimulation increased retinal arterial diameters by +1.6% (1.8%) (mean, p<0.001 v baseline), +2.8% (SD 2.2%) (p<0.001) and +2.8% (1.6%) (p<0.001) during 16, 32, and 64 seconds of flicker stimulation, respectively. In diabetic patients flicker had no effect on arterial vessel diameters: +0.1% (3.1%) (16 seconds, p=0.9), +1.1% (2.7%) (32 seconds, p=0.07), +1.0% (2.8%) (64 seconds, p=0.1). In retinal veins, the response to flicker light was not significantly different in both groups. Retinal venous vessel diameters increased by +0.7% (1.6%) (16 seconds, p<0.05), +1.9% (2.3%) (32 seconds, p<0.001) and +1.7% (1.8%) (64 seconds, p<0.001) in controls during flicker stimulation. Again, no increase was observed in the patients group: +0.6% (2.4%), +0.5% (1.5%), and +1.2% (3.1%) (16, 32, and 64 seconds, respectively).

Conclusion: Flicker responses of retinal arteries and veins are abnormally reduced in patients with IDDM with no or mild non-proliferative retinopathy. Whether this diminished response can be attributed to altered retinal vascular reactivity or to decreased neural activity has yet to be clarified.

Methods

Subjects

The study protocol was approved by the ethics committee of the Vienna University School of Medicine and followed the guidelines set forth in the Declaration of Helsinki. All patients signed a written informed consent and passed a screening examination before the study day.

Twenty six patients with early IDDM and 26 control subjects matched for sex and age, body mass index between 15th and 85th percentile were enrolled in this assessor masked, controlled clinical study. Every subject had to pass an ophthalmic examination including slit lamp biomicroscopy, indirect funduscopy, and measurement of intraocular pressure (IOP) with Goldmann applanation tonometry. Inclusion criteria of patients were insulin dependent diabetes mellitus (IDDM) with non or mild non-proliferative retinopathy. The eyes were classified according to the Modified Airlie House Classification. Patients with no signs of diabetic retinopathy (level 1) or patients with one or more microaneurysms (level 2) were included. In all subjects the right eye was studied.

Exclusion criteria were non-insulin dependent diabetes, maturity onset diabetes of the young (MODY diabetes), any sign of non-diabetes induced vascular pathologies, systemic hypertension (defined as systolic blood pressure >150 mm Hg, diastolic blood pressure >90 mm Hg), treatment with vasoactive drugs except insulin, presence of intraocular pathology other than diabetic retinopathy, ametropia of less than 3 dioptres, and anisometropia of less than 1 dioptre.

Zeiss retinal vessel analyser (RVA)

Retinal vessel diameters were evaluated with the RVA. The RVA is a commercially available system which comprises a fundus camera (Zeiss FF 450, Jena, Germany), a video camera, a high resolution video recorder, a real time monitor, and a personal computer with a vessel diameter analysing.
Table 1 Main patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>Diabetes group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex (male/female)</td>
<td>14/12</td>
<td>14/12</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>47 (14)</td>
<td>47 (14)</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>6.6 (1.0)</td>
<td>–</td>
</tr>
<tr>
<td>Diabetes duration (years)</td>
<td>10 (8)</td>
<td>–</td>
</tr>
<tr>
<td>Intraocular pressure (mm Hg)</td>
<td>13 (2)</td>
<td>13 (2)</td>
</tr>
<tr>
<td>MAP (mm Hg)</td>
<td>83 (10)</td>
<td>86 (11)</td>
</tr>
<tr>
<td>Diabetic retinopathy (level 1/level 2)</td>
<td>12/14</td>
<td>–</td>
</tr>
</tbody>
</table>

Diabetic retinopathy was assessed according to the Modified Airlie House Classification (level 1: no retinopathy; level 2: one or more microaneurysms).

Flickering light stimulation

For flicker stimulation a custom built device was used, stimulating with light flashes at a frequency of 8 Hz. Flicker was generated by focusing the light of a 150 W halogen light source on a rotating sector disc producing a square wave light pattern with a modulation depth of 100%. Using an optical fibre, flicker stimuli were delivered to the eye through the illumination pathways of the fundus camera of the RVA. The flicker was centred in the macula with an angle of approximately 30 degrees.

A wavelength separation technique was used to spectrally separate the flicker light from that used to illuminate the fundus. For flicker stimulation, white light in combination with a 550 nm low pass cut-off filter was used. This ensures that only light with wavelengths below 550 nm is used for flicker stimulation. To separate the flickering light from the light illuminating the fundus, an interference filter with a centre wavelength of 577 nm and a bandwidth of 10 nm (Laser Components, Olchingen, Germany) was placed in front of the light source of the fundus camera of the RVA. The flicker was centred in the macula with an angle of approximately 30 degrees.

A wavelength separation technique was used to spectrally separate the flicker light from that used to illuminate the fundus. For flicker stimulation, white light in combination with a 550 nm low pass cut-off filter was used. This ensures that only light with wavelengths below 550 nm is used for flicker stimulation. To separate the flickering light from the light illuminating the fundus, an interference filter with a centre wavelength of 577 nm and a bandwidth of 10 nm (Laser Components, Olchingen, Germany) was placed in front of the light source of the fundus camera. The flicker was centred in the macula with an angle of approximately 30 degrees.

Assessment of HbA1c values

Blood HbA1c values were assessed using a standard HPLC laboratory method by the Department of Clinical Chemistry, University of Vienna, Austria.

Experimental paradigm

All measurements were done in the right eye according to the following time schedule. After a short resting period to obtain stable haemodynamic conditions, diameter measurements with the RVA were performed. Retinal vessel diameters were continuously measured for 352 seconds. Diffuse luminance

Figure 1 Box (mean, 25% and 75% CI) and whisker (5% and 95% CI) plot of flicker response (percentage changes) as recorded after 16, 32, and 64 seconds of flicker stimulation.
patients had to be excluded from the analysis. The remaining data of 24 arteries and 24 veins have been used for data analysis. Main patients characteristics are given in table 1. Retinal vessel diameters, mean arterial pressure and intraocular pressure were comparable between both groups. Both retinal arterial and venous vessel diameters at the measurement site were comparable between patients with diabetes and healthy controls. Absolute values of retinal vessel diameters are given in table 2.

In retinal arteries, the response to stimulation with diffuse luminance flicker was significantly diminished in diabetic patients compared to healthy volunteers (ANOVA, p = 0.0031, df = 46, F = 9.743). In healthy controls, flicker stimulation increased retinal arterial vessel diameters by +1.6% (1.8%) (p<0.001, t test flicker v baseline), +2.8% (2.2%) (p<0.001) and +2.8% (1.6%) (p<0.001) during 16, 32, and 64 seconds of flicker, respectively. In diabetic patients, no effect of flickering light on arterial vessel diameters was observed: +0.1% (3.1%) (16 seconds, p = 0.9), +1.1% (2.7%) (32 seconds, p = 0.07), and +1.0% (2.8%) (64 seconds, p = 0.1) (fig 1).

Response of retinal venous diameters was not significantly different in diabetic compared to healthy volunteers (ANOVA, p = 0.186, df = 46, F = 1.804). However, in diabetic patients no significant increase in venous vessel diameters was observed during stimulation with diffuse luminance flicker: +0.6 (2.4) (16 seconds, p<0.2), +0.5 (1.5) (32 seconds, p<0.1), and +1.2 (3.1) (64 seconds, p<0.06). In contrast, retinal venous vessel diameters increased by +0.7% (1.6%) (16 seconds, p<0.05), +1.9% (2.3%) (32 seconds, p<0.001), 1.7% (1.8%) (64 seconds, p<0.001) in healthy volunteers during flicker stimulation.

No correlation was found between flicker response and HbA1c values or diabetes duration (data not shown).

### DISCUSSION

The results of this study indicate that the response of retinal vascular parameters to flicker stimulation is significantly reduced in patients with early stage diabetic retinopathy. Whereas retinal arteries and veins dilate in the order of 2–3% in healthy volunteers, no significant increase could be observed in patients with early stage diabetes.

There is compelling evidence now that vascular tone and blood flow regulation are affected in diabetic patients. Several studies revealed an increase in blood flow, induced by short time hyperglycaemia, mainly attributable to an increase in blood flow velocity.20–22 Furthermore, it has been shown that retinal perfusion is already increased in patients with early IDDM with a diabetes duration of less than 4 years23 and that retinal vasodilatation may precede other signs of retinopathy.24 In contrast, other reports indicate that blood flow may be decreased in early stage diabetes.25–26

In addition, the regulatory capacity of retinal vessels appears to be affected in the diseased retina. This has been shown in several animal and human studies showing that diabetes is associated with an abnormal retinal vascular response to hyperoxia11,14 and abnormal retinal autoregulation.13–14 These results are compatible with the data of the current study indicating that the response of retinal vessels to stimulation with diffuse luminance flicker is significantly reduced in diabetic patients.

At least two mechanisms may be attributable to the blunted flicker response in diabetic patients. Firstly, the blunted flicker response in diabetic patients could reflect retinal damage caused by vascular abnormalities. Among others, one of the earliest alterations in diabetic retinas have been found to include pericyte loss,27 which could alter responsiveness to locally generated mediators. It has been suggested that diabetic patients have either increased nitric oxide (NO) synthase activity or decreased vascular sensitivity to NO.2 This is important for the results of the present study because NO appears to play a part in flicker induced vasodilatation.28–30 On the other hand neural activity in the retina may be altered before any clinical signs of retinopathy are evident. Measurements of oscillatory potentials or pattern responses demonstrated that ERG abnormalities occur before any signs of clinically evident retinopathy.29–30 Several lines of evidence indicate that the increase in retinal and optic nerve head blood flow in response to flicker stimulation may be a direct consequence of an increase in retinal neural activity, mainly attributable to increased ganglion cell activity.3 The increase in optic nerve head blood flow shows similar characteristics to the first and second harmonic amplitudes of the flicker electroretinogram, indicating that blood flow changes in response to flickering light stimulation are a consequence of increased neural activity.3 Hence the results of the present study may also be compatible with the idea of reduced neural activity and leading to a decreased flicker response in diabetes.

One has to consider that our results are limited by the fact that we can only provide information about retinal vessels diameter and the reactivity of retinal vessels to flicker stimulation, not about changes in blood flow per se. In view of the fact that blood flow in a main retinal vessel is $\pi D^2 V_{\text{mean}}/4$, where $D$ is the vessel diameter and $V$ the mean velocity of the blood, a twofold change in diameter produces a fourfold change in blood flow. Whereas this underlines the importance of getting information about vessel diameters for estimating blood flow in the retina, one has to keep in mind that for determination of blood flow, information on blood flow velocity is crucial. Thus, we cannot exclude that even though the diameters of the large retinal arteries and veins showed no measurable changes during flicker stimulation in the patients with diabetes, the blood flow may have increased at these sites owing to an increase in blood speed.

To finally answer this question, combined measurements of vessel diameters and red blood cell velocity, which would allow for determination of blood flow, would be necessary. In principle, bidirectional laser Doppler velocimetry is capable of measuring red blood velocity in major retinal vessel.32 However, to obtain reproducible flicker responses with this

### Table 2 Absolute arterial and venous vessel diameter before and during flicker stimulation. Data are presented as means (SD)

<table>
<thead>
<tr>
<th>Flicker time (seconds)</th>
<th>Arterial vessel diameter (μm)</th>
<th>Venous vessel diameter (μm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diabetes group</td>
<td>Control group</td>
</tr>
<tr>
<td></td>
<td>Before flicker</td>
<td>During flicker</td>
</tr>
<tr>
<td></td>
<td>Before flicker</td>
<td>During flicker</td>
</tr>
<tr>
<td>16</td>
<td>122.6 (15.7) (16 seconds, p&lt;0.001)</td>
<td>122.6 (15.7) (16 seconds, p&lt;0.001)</td>
</tr>
<tr>
<td>32</td>
<td>121.8 (14.8) (32 seconds, p&lt;0.001)</td>
<td>121.8 (14.8) (32 seconds, p&lt;0.001)</td>
</tr>
<tr>
<td>64</td>
<td>123.2 (15.8) (64 seconds, p&lt;0.001)</td>
<td>123.2 (15.8) (64 seconds, p&lt;0.001)</td>
</tr>
</tbody>
</table>

Asterisks indicate level of significance.

$\pi D^2 V_{\text{mean}}/4$, where $D$ is the vessel diameter and $V$ the mean velocity of the blood, a twofold change in diameter produces a fourfold change in blood flow. Whereas this underlines the importance of getting information about vessel diameters for estimating blood flow in the retina, one has to keep in mind that for determination of blood flow, information on blood flow velocity is crucial. Thus, we cannot exclude that even though the diameters of the large retinal arteries and veins showed no measurable changes during flicker stimulation in the patients with diabetes, the blood flow may have increased at these sites owing to an increase in blood speed.
system is difficult, especially in patients, because excellent target fixation is required.

Interestingly, flicker response is altered in retinal arteries but failed to reach a level of significance in retinal veins. Whether this is simply related to the smaller percentage change in retinal veins during flicker stimulation is unclear. One has, however, to consider that vasodilatation of retinal veins is primarily a passive effect. As the microcirculation is the most important site of vascular resistance, data on the retinal microvasculature are required to elucidate this behaviour. Owing to the limited resolution of the RVA, we cannot finally answer this question. This problem applies also to the other methods that have been previously proposed to measure retinal vessel size in vivo.33–36

In the current study we measured the response of one retinal artery and vein only. Thus, we cannot exclude that retinal vessels were already predilated in diabetic patients, which could also contribute to the diminished flicker response. This is strengthened by the fact that the total retinal venous diameter, calculated by adding the cross section of each visible vein observed around the optic disc, is increased in patients with diabetes.33 However, changes in retinal vessel diameters between diabetics and healthy controls are difficult to evaluate because of the high interindividual differences in retinal vascular architecture.

In conclusion, retinal vasodilatation caused by stimulation of fundus microvascularity are required to elucidate this behaviour. Owing to the limited resolution of the RVA, we cannot finally answer this question. This problem applies also to the other methods that have been previously proposed to measure retinal vessel size in vivo.33–36

ACKNOWLEDGEMENTS

Financial support of the “Fonds zur Förderung der wissenschaftlichen Forschung” Grant No. P14262 is gratefully acknowledged. Furthermore, the authors thank Dr Selim Orgül, Basle for his advises in statistical analysis of the data.

Authors’ affiliations

G Garhofer, C Zawinka, H Resch, P Kathy, L Schmetterer, G T Dorner, Department of Clinical Pharmacology, University of Vienna, Austria

G Garhofer, G T Dorner, Department of Ophthalmology, University of Vienna, Austria

P Kathy, Department of Ophthalmology, Semmelweis University, Budapest, Hungary

L Schmetterer, Institute of Medical Physics, University of Vienna, Austria

Correspondence to: G T Dorner, Department of Clinical Pharmacology, Währinger Gürtel 18-20, A-1090 Vienna, Austria: guidedorner@univie.ac.at

Accepted for publication 1 December 2003

REFERENCES


Treatment for amblyopia can wait until school entry

Treatment for mild amblyopia in one eye can safely be left beyond preschool years, according to a randomised controlled trial in the UK. The implications are far reaching as screening and treatment are practised worldwide.

The single blind trial established that full treatment with glasses and eye patch benefited preschool children (age 3–5 years) with moderate (6/36–6/18) amblyopia, whose improved vision translated into one or two lines of the Snellen chart, but not those with mild (6/9–6/12) amblyopia over untreated children. Six months afterwards, when all children in need of glasses had them, the difference in visual acuity among the three groups was minimal, further suggesting that delay did no harm.

The trial assessed standard treatment for amblyopia—a patch and glasses—and glasses alone against no treatment in 177 children with amblyopia identified at standard preschool screening and referred to one of eight children’s eye clinics. Impairment ranged from 6/9–6/36. Children randomised to treatment had an initial assessment and reassessments at 24, 52, 54, and 78 weeks. Those receiving a patch and glasses had their patch fitted after six weeks’ wearing glasses, if indicated. Glasses were prescribed after 52 weeks for any child in any group who needed them and eye patches two weeks later.

Preschool screening is widespread owing to the belief that amblyopia is treatable only up to age 7 years, but its cost effectiveness and psychological impact have been queried. A systematic review has previously claimed that evidence in favour of treatment is lacking.